Try our beta test site
205 studies found for:    ibrutinib
Show Display Options
Rank Status Study
1 Recruiting RICE-ibrutinib in Relapsed DLBCL
Conditions: Diffuse Large B Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Recurrent
Intervention: Drug: Ibrutinib-RICE
2 Recruiting A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Ibrutinib
3 Not yet recruiting Combination of Ibrutinib and As2O3 in the Treatment of CLL
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: Ibrutinib combined with As2O3;   Drug: ibrutinib
4 Recruiting Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
Condition: Cancer
Intervention: Drug: SNX-5422 plus ibrutinib
5 Not yet recruiting Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: ruxolitinib;   Drug: ibrutinib
6 Recruiting Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma
Condition: Gastrooesophageal Cancer
Intervention: Drug: ibrutinib
7 Completed A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants
Condition: Healthy Participants
Intervention: Drug: Ibrutinib
8 Recruiting Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
Condition: Cancer
Intervention: Drug: SNX-5422 plus ibrutinib
9 Active, not recruiting An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Relapsed or Refractory Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
10 Active, not recruiting Ublituximab + Ibrutinib in Select B-cell Malignancies
Conditions: Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
Interventions: Drug: Ublituximab;   Drug: Ibrutinib
11 Completed Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-cell
Intervention: Drug: Ibrutinib
12 Recruiting Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Condition: High Risk Smoldering Multiple Myeloma
Intervention: Drug: Ibrutinib
13 Recruiting Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Conditions: Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL);   Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Interventions: Drug: Ibrutinib;   Drug: HD- Methotrexate (MTX);   Drug: Rituximab + HD- Methotrexate (MTX)
14 Active, not recruiting A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Condition: Lung Cancer
Intervention: Drug: Ibrutinib
15 Recruiting A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
Condition: Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib + GA101 +GDC-0199
16 Active, not recruiting A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Condition: Lymphocytic Leukemia
Intervention: Drug: Ibrutinib
17 Active, not recruiting Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Behavioral: Phone Calls
18 Recruiting Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Carcinoid Tumors;   Pancreatic NET
Intervention: Drug: Ibrutinib
19 Recruiting Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Conditions: T-cell Lymphoma;   Relapsed and Refractory T-cell Lymphoma
Intervention: Drug: Ibrutinib
20 Recruiting Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Nivolumab;   Drug: Ibrutinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.